Relevance of the CYP3A4*20 variant as a predictor of paclitaxel-induced neuropathy in the Spanish population
Med Clin (Barc). 2018 Feb 23;150(4):163-164.
doi: 10.1016/j.medcli.2017.09.004.
Epub 2017 Oct 18.
[Article in
English,
Spanish]
Affiliations
- 1 Servicio de Genética, Hospital de la Santa Creu i Sant Pau, Barcelona, España; Universidad de Barcelona (UB), Barcelona, España.
- 2 Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, España.
- 3 Servicio de Genética, Hospital de la Santa Creu i Sant Pau, Barcelona, España; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) U-705, Instituto de Salud Carlos III, Madrid, España. Electronic address: jsalazar@santpau.cat.
No abstract available
MeSH terms
-
Antineoplastic Agents, Phytogenic / adverse effects*
-
Cytochrome P-450 CYP3A / genetics*
-
Genetic Markers
-
Genotype
-
Humans
-
Paclitaxel / adverse effects*
-
Peripheral Nervous System Diseases / chemically induced*
-
Spain
Substances
-
Antineoplastic Agents, Phytogenic
-
Genetic Markers
-
Cytochrome P-450 CYP3A
-
CYP3A4 protein, human
-
Paclitaxel